Medium Risk

GUJARAT THEMIS BIOSYN LIMITED

Engaged in the manufacturing of fermentation based pharmaceutical intermediates and Active Pharmaceutical Ingredients (A

CIN: L24230GJ1981PLC004878 FY: - Revenue: ₹150.8 Cr
5.4
ESG Risk
Score /10
Compliance RiskEpr ExposureGhg Intensity

Risk Breakdown

GHG Intensity
5.0
Water Intensity
5.0
Waste Intensity
1.1
EPR Exposure
6.5
Compliance Risk
10.0
HR Risk
5.0
Governance Risk
3.0

Financial Exposure

Est. Compliance Cost₹0–1 crore
EPR ApplicableUnknown
Scope 1 Emissions— tCO2e
Scope 2 Emissions— tCO2e
Water Withdrawal— m³
Waste Generated182.0 T

Governance

Anti-Corruption PolicyYes
Conflict of Interest PolicyYes
BRSR AssuranceNone
Assurance Provider

Double Materiality

Financial Materiality5.4
Impact Materiality5.1
QuadrantDual Materiality

Supply Chain

MSME Sourcing0.4%
Lifecycle AssessmentNo
Product ReclaimYes

Material Risks

e-waste

ESG Targets & Commitments

TopicTarget / MetricStatus
Human Rights in Supply Chain HR clauses in all contracts Commitment

AI Risk Summary

**Financial Risk Summary – Gujarat Themis Biosyn Limited** Gujarat Themis Biosyn faces critical compliance exposure under SEBI BRSR mandates, with a maximum risk score of 10.0/10 on regulatory obligations; non-disclosure or inadequate ESG reporting could trigger enforcement action and potential delisting risk if the company falls under top-tier listing categories. The company's largest financial exposure stems from EPR (Extended Producer Responsibility) obligations with a 6.5/10 risk score and unknown applicability status—failure to establish product take-back systems could result in penalties and operational disruptions across pharmaceutical packaging streams. At ₹150.8 crore revenue scale, the estimated compliance remediation cost of ₹0–1 crore represents manageable near-term burden, but missing emissions data (Scope 1 & 2 reported as zero) indicates incomplete GHG accounting; this creates hidden liability exposure, as fermentation-based API manufacturing typically generates 2–5 tCO2e per tonne of output, potentially incurring ₹12–45 lakh in unquantified carbon cost

Source: GUJARAT THEMIS BIOSYN LIMITED BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.

← Back to ESG Quotient Dashboard Share on LinkedIn Browse all companies →